A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00189254|
Recruitment Status : Completed
First Posted : September 19, 2005
Last Update Posted : November 29, 2016
|Condition or disease||Intervention/treatment||Phase|
|Actinic Keratoses||Drug: Imiquimod||Phase 3|
|Study Type :||Observational|
|Estimated Enrollment :||72 participants|
|Official Title:||A Follow-up Study to Evaluate Actinic Keratosis Recurrence Rates One Year After Completion of the 1487-IMIQ Study|
|Study Start Date :||April 2005|
|Primary Completion Date :||November 2005|
|Study Completion Date :||November 2005|
Imiquimod 5% cream
No investigational treatments were given during this study.
No defined treatments were given during this study.
- Efficacy [ Time Frame: one year after completion of study 1487-Imiq ]Efficacy was evaluated by counting AK lesions in the previous treatment area. Subjects at the 1-year follow-up visit with recurrence of lesion(s).
- Safety [ Time Frame: one year after completion of study 1487-Imiq ]Safety was evaluated by assessing the area of previous treatment for LSRs and skin quality
- Adverse Events [ Time Frame: one year after completion of study 1487-Imiq ]AEs considered by investigator to be possibly or probably related to the 1487-Imiq study medication were documented and recorded.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00189254
|Study Chair:||Study Coordinator||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|